iTeos Therapeutics, Inc. ITOS · Stock Open iTeos Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
iTeos Therapeutics, Inc. Analysis (ITOS)
Is iTeos Therapeutics, Inc. a good investment? iTeos Therapeutics, Inc. (ITOS) is currently trading at 10.15 USD. Market analysts have a consensus price target of 10.64 USD. This suggests a potential upside from current levels.
Investor FAQ
Does iTeos Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is iTeos Therapeutics, Inc.?
iTeos Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Community Discussion